Anthropic Acquires Stealth Biotech Startup Coefficient Bio in $400 Million Stock Deal

Anthropic acquired stealth biotech startup Coefficient Bio for $400 million in stock, bringing ex-Genentech AI drug discovery researchers into its healthcare division.

Anthropic Acquires Stealth Biotech Startup Coefficient Bio in $400 Million Stock Deal Anthropic acquired stealth biotech startup Coefficient Bio for $400 million in stock, bringing ex-Genentech AI drug discovery researchers into its healthcare division. Aaron Rafferty April 03, 2026 Key Takeaways: Anthropic acquired Coefficient Bio, an 8-month-old stealth AI biotech startup, for just over $400 million in stock, bringing fewer than 10 ex-Genentech computational biologists into its healthcare division. Coefficient Bio's team, led by co-founders Samuel Stanton and Nathan C. Frey, built AI models for protein and antibody design that achieved 97-100% expression success rates in lab validation, winning an ICLR 2024 Outstanding Paper Award. The deal represents roughly 0.1% dilution against Anthropic's $380 billion post-money valuation and positions the company against DeepMind's AlphaFold in the race to own the full AI drug discovery pipeline. Anthropic acquired Coefficient Bio in an all-stock deal valued at just over $400 million, The Information reported on April 2, with TechCrunch and Newcomer confirming the close. The startup was formally founded roughly eight months ago, had fewer than 10 employees, no publicly known product, and no disclosed revenue. What it had was a team of ex-Genentech computational biologists with rare credentials in AI-driven drug discovery. Co-founder Nathan C. Frey previously led multidisciplinary teams at Prescient Design, Genentech's computational drug discovery unit, working on biological foundation models and lab-in-the-loop autonomous systems. His co-authored paper on protein discovery using a method called discrete walk-jump sampling (dWJS) won an ICLR 2024 Outstanding Paper Award , generating functional antibodies with 97-10